Komori
Kissei Pharmaceutical (4547) · InitiativeAdvanced

Share Buybacks and Cancellations as Flexible Capital Policy Measures

First written in FY2016. 13 of 17 entries say "Advanced", first in FY2017-Q3. Latest entry: FY2026.

17entries
11years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2017-Q3 – FY2018OtherFY2019AdvancedFY2024-Q1 – FY20262016: 120162017: 220172018: 220182019: 120192020: 020202021: 020212022: 020222023: 220232024: 320242025: 220252026: 42026
Same theme, other companies
Shareholder Returns and Capital Policy through Treasury Share Acquisitions and CancellationsA theme 214 companies write about · 0 as a headwind · 215 as a tailwind

93 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 216 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「At a meeting of the Board of Directors held on 11 May 2026, the company resolved to acquire treasury shares pursuant to Article 156 of the Companies Act as applied with the necessary changes under Article 165, paragraph 3 of the Act, as set out below, and to cancel treasury shares pursuant to Article 178 of the Act.」

    In May 2026, the company resolved to acquire up to 1.3 million treasury shares for a total of ¥6 billion and cancel all shares acquired. This further specified the capital policy under Beyond 80.
  2. FY2026-H1AdvancedAnnual report

    「Based on a resolution of the Board of Directors held on 7 May 2025, the company acquired 1,369,200 treasury shares for ¥5,216 million. It also cancelled 1,369,200 treasury shares for ¥4,173 million on 27 June 2025.」

    As an additional implementation of the treasury-share acquisition plan under Beyond 80, the company acquired 1,369,200 shares for ¥5,216 million and cancelled the same number of shares.
  3. FY2025RaisedAnnual report

    「The acquisition, disposal and cancellation of treasury shares will be carried out flexibly in line with business developments based on resolutions of the Board of Directors, with increasing shareholder value as the primary objective. During the five-year period of the medium-term management plan Beyond 80, we plan total treasury-share acquisitions of ¥30 billion, using ¥6 billion per year as a guideline.」

    The company newly specified a plan under which treasury-share acquisitions would total ¥30 billion over the five years of Beyond 80, using ¥6 billion per year as a guideline. During the fiscal year, it acquired 1.4 million shares for ¥5,293 million and cancelled the same number of shares.
  4. FY2025-H1AdvancedAnnual report

    「At a meeting of the Board of Directors held on 5 November 2024, the company resolved, pursuant to Article 156 of the Companies Act as applied with the necessary changes under Article 165, paragraph 3 of the Act, to acquire treasury shares and determine the specific acquisition method, and carried out the acquisition as follows. (2) Total number of shares acquired: 1,400,000 shares (3) Total acquisition price of shares acquired: ¥5,292,000,000 At a meeting of the Board of Directors held on 5 November 2024, the company resolved to cancel treasury shares pursuant to Article 178 of the Companies Act. (2) Total number of shares to be cancelled: 1,400,000 shares」

    The company reported the acquisition of 1.4 million treasury shares for ¥5,292 million and the resolution and implementation of the cancellation of the same number of shares, representing an additional implementation of its flexible capital policy.
  5. FY2024AdvancedAnnual report

    「Based on a resolution of the Board of Directors held on 8 May 2023, the company acquired 1,909,900 treasury shares for ¥5,999 million. It also cancelled 2,500,000 treasury shares for ¥5,704 million on 12 June 2023.」

    The acquisition results for treasury shares advanced to 1,909,900 shares and ¥5,999 million, and the cancellation of 2,500,000 shares was confirmed as completed.
  6. FY2024-Q3AdvancedAnnual report

    「Based on a resolution of the Board of Directors held on 8 May 2023, the company acquired 1,664,100 treasury shares for ¥5,196 million. It also cancelled 2,500,000 treasury shares for ¥5,704 million on 12 June 2023.」

    The acquisition results for treasury shares were updated to 1,664,100 shares and ¥5,196 million, and the cancellation of 2,500,000 shares for ¥5,704 million was reconfirmed as completed.
  7. FY2024-Q2AdvancedAnnual report

    「Based on a resolution of the Board of Directors held on 8 May 2023, the company acquired 314,600 treasury shares for ¥949 million. It also cancelled 2,500,000 treasury shares for ¥5,704 million on 12 June 2023.」

    The acquisition results for treasury shares were updated to 314,600 shares and ¥949 million, and the cancellation of 2,500,000 shares was recorded as completed.
  8. FY2024-Q1AdvancedAnnual report

    「Based on a resolution of the Board of Directors held on 8 May 2023, the company acquired 192,400 treasury shares for ¥556 million. It also cancelled 2,500,000 treasury shares for ¥5,704 million on 12 June 2023.」

    The company acquired 192,400 treasury shares and cancelled 2.5 million shares, moving its flexible capital policy into a new implementation phase.
  9. FY2019Reduction in acquisition resultsAnnual report

    「Treasury shares acquired during the fiscal year 93 286,294」

    The acquisition of treasury shares during the fiscal year was limited to the purchase of 93 shares constituting less than one trading unit, representing a reduction from the acquisition of 1.6 million shares carried out in the previous fiscal year.
  10. FY2018AdvancedAnnual report

    「The company acquired and cancelled treasury shares.」

    During the fiscal year, the company acquired 1.6 million treasury shares for an acquisition price of ¥4,462.40 million and cancelled 2.5 million shares. The acquisition and cancellation of treasury shares moved from the resolution stage to the implementation stage.
  11. FY2018-Q3AdvancedAnnual report

    「At a meeting of the Board of Directors held on 9 February 2018, the company resolved to acquire treasury shares and the specific acquisition method pursuant to Article 156 of the Companies Act as applied with the necessary changes under Article 165, paragraph 3 of the Act, and to cancel treasury shares pursuant to Article 178 of the Act.」

    The company resolved to acquire up to 1,800,000 treasury shares and cancel 2,500,000 shares to enable a flexible capital policy, improve capital efficiency and enhance shareholder returns.
  12. FY2017AdvancedAnnual report

    「Funds used in financing activities amounted to ¥3,766 million, an increase of ¥1,620 million in outflows compared with the previous consolidated fiscal year. The main factor was the acquisition of treasury shares.」

    During the fiscal year, the company acquired 610,000 treasury shares for an acquisition price of ¥1,649.61 million.
  13. FY2017-Q3AdvancedAnnual report

    「There were changes including a decrease in the valuation difference on other securities and the acquisition of treasury shares, as well as an increase in retained earnings. As of the end of the third quarter accounting period, the number of shares held in the company's own name was 5,994,175.」

    The company reported the acquisition of treasury shares during the cumulative third-quarter period, demonstrating the specific implementation of a flexible capital policy through treasury-share acquisitions.
  14. FY2016First statedAnnual report

    「To enable the flexible execution of capital policies in response to changes in the business environment, the company provides in its Articles of Incorporation, pursuant to Article 165, paragraph 2 of the Companies Act, that it may acquire its own shares through market transactions and other means by resolution of the Board of Directors.」

    During the fiscal year, the company cancelled 2,600,000 treasury shares, leaving 5,383,634 treasury shares at the fiscal year-end.
Moved together

"Establishing a Competitive Advantage and Securing Sales in the Domestic Prescription Pharmaceutical Market" moved the same way as this thread, in the same document, in 13 of its 17 moves.

131212111010★123456
  1. ★This thread
  2. 1Establishing a Competitive Advantage and Securing Sales in the Domestic Prescription Pharmaceutical Market13×
  3. 2Enhancing and Strengthening a Product Portfolio with Distinctive Features and Competitive Advantages12×
  4. 3Stable dividends and profit allocation in line with earnings12×
  5. 4Efficient Advancement of Clinical Trials for Development Programs and Early Approval11×
  6. 5Promoting overseas expansion and stabilizing the overseas earnings base10×
  7. 6Creating New Drugs Through Development Pipelines and External Partnerships10×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Kissei Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the Treasury shares of 2026-05-11: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Share Buybacks and Cancellations as Flexible Capital Policy Measures | KISSEI PHARMACEUTICAL CO.,LTD. (4547) | Komori